Literature DB >> 21047635

Avoiding the use of human chorionic gonadotropin combined with oocyte vitrification and GnRH agonist triggering versus coasting: a new strategy to avoid ovarian hyperstimulation syndrome.

Leyre Herrero1, Sandra Pareja, Carolina Losada, Ana Cristina Cobo, Antonio Pellicer, Juan Antonio Garcia-Velasco.   

Abstract

In this observational trial, we compared the impact on two different strategies, egg vitrification (n = 152) obtained after triggering final oocyte maturation with GnRH agonists and transferring the embryos at a later stage, with classical coasting (n = 96) to avoid OHSS in patients at risk due to high response to COH. Our results show that oocyte vitrification after GnRH agonists triggering is a highly attractive, safe, and efficient alternative to postpone embryo transfer in patients at high risk of OHSS, resulting in decreased risk for the patient and a better cycle outcome (pregnancy rate 50% vs 29.5%).
Copyright © 2011 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21047635     DOI: 10.1016/j.fertnstert.2010.09.040

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  11 in total

1.  Different ART outcomes at increasing peak estradiol levels with long and antagonist protocols: retrospective insights from ten years experience.

Authors:  Massimo Manno; Marta Cervi; Donatella Zadro; Giuseppa Fuggetta; Valter Adamo; Francesco Tomei
Journal:  J Assist Reprod Genet       Date:  2011-04-26       Impact factor: 3.412

2.  A combination of hydroxypropyl cellulose and trehalose as supplementation for vitrification of human oocytes: a retrospective cohort study.

Authors:  Aila Coello; Pilar Campos; José Remohí; Marcos Meseguer; Ana Cobo
Journal:  J Assist Reprod Genet       Date:  2016-01-11       Impact factor: 3.412

Review 3.  The state of "freeze-for-all" in human ARTs.

Authors:  Natalia Basile; Juan A Garcia-Velasco
Journal:  J Assist Reprod Genet       Date:  2016-09-14       Impact factor: 3.412

4.  Ovarian hyperstimulation syndrome after gonadotropin-releasing hormone agonist triggering and "freeze-all": in-depth analysis of genetic predisposition.

Authors:  Samuel Santos-Ribeiro; Nikolaos P Polyzos; Katrien Stouffs; Michel De Vos; Sara Seneca; Herman Tournaye; Christophe Blockeel
Journal:  J Assist Reprod Genet       Date:  2015-05-17       Impact factor: 3.412

5.  Rescue In Vitro Maturation in Polycystic Ovarian Syndrome Patients Undergoing In Vitro Fertilization Treatment who Overrespond or Underrespond to Ovarian Stimulation: Is It A Viable Option? A Case Series Study.

Authors:  Muhammad Fatum; Marie Eve Bergeron; Caroline Ross; Anni Ding; Ayesha Bhevan; Karen Turner; Tim Child
Journal:  Int J Fertil Steril       Date:  2020-07-15

6.  Combination of cabergoline and embryo cryopreservation after GnRH agonist triggering prevents OHSS in patients with extremely high estradiol levels--a retrospective study.

Authors:  Yu-Hung Lin; Mei-Zen Huang; Jiann-Loung Hwang; Heng-Ju Chen; Bih-Chwen Hsieh; Lee-Wen Huang; Chii-Ruey Tzeng; Kok-Min Seow
Journal:  J Assist Reprod Genet       Date:  2013-04-20       Impact factor: 3.412

7.  GnRH analogues in the prevention of ovarian hyperstimulation syndrome.

Authors:  Pilar Alama; Jose Bellver; Carmen Vidal; Juan Giles
Journal:  Int J Endocrinol Metab       Date:  2013-04-01

Review 8.  Oocyte, embryo and blastocyst cryopreservation in ART: systematic review and meta-analysis comparing slow-freezing versus vitrification to produce evidence for the development of global guidance.

Authors:  Laura Rienzi; Clarisa Gracia; Roberta Maggiulli; Andrew R LaBarbera; Daniel J Kaser; Filippo M Ubaldi; Sheryl Vanderpoel; Catherine Racowsky
Journal:  Hum Reprod Update       Date:  2017-03-01       Impact factor: 15.610

9.  Ectopic pregnancy risk factors for ART patients undergoing the GnRH antagonist protocol: a retrospective study.

Authors:  A Weiss; R Beck-Fruchter; J Golan; M Lavee; Y Geslevich; E Shalev
Journal:  Reprod Biol Endocrinol       Date:  2016-03-23       Impact factor: 5.211

10.  Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.

Authors:  L L Engmann; B S Maslow; L A Kaye; D W Griffin; A J DiLuigi; D W Schmidt; D R Grow; J C Nulsen; C A Benadiva
Journal:  J Ovarian Res       Date:  2019-01-26       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.